Results 101 to 110 of about 49,423 (253)
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1174-1184, June 2025.Patients with alopecia areata received etrasimod 2 mg, 3 mg or placebo oncedaily for 24 weeks, followed by a 28‐week open‐label extension period. Overall, etrasimod 2 mg and 3 mg were safe and well tolerated in patients; their efficacy was numerically higher than placebo and appeared to be dose dependent.
B. King +5 more
wiley +1 more source
AN AYURVEDIC MULTIMODULAR TREATMENT OF ALOPECIA TOTALIS (KHALITYA) W.R.T PANCHAKARMA: A CASE REPORT [PDF]
, 2019 Alopecia areata is characterized by circumscribed non-scarring loss of hair in single or multiple patches over the scalp or body hair. Histopathology shows perifollicular and intrafollicular inflammatory cells infiltrate composed mainly of lymphocytes ...
Aosemba Jamir +4 more
core +1 more source
Alopecia: evaluation and treatment [PDF]
, 2011 Hair loss is a very common complaint. Patients may describe increased shedding and diffuse or localized alopecia. The differential diagnosis of hair loss includes a number of disorders causing cicatricial or noncicatricial alopecias. This paper describes
Gordon, Katherine A, Tosti, Antonella
core +2 more sources
Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata
Dermatology Practical & Conceptual, 2023 Introduction: Alopecia areata (AA) is a non-scarring, autoimmune hair loss disorder, varying in severity from small round hairless patches to the total loss of scalp or body hair. Steroid pulse therapy outcomes for AA vary.
Fatemeh Rastaghi +4 more
doaj +1 more source
Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
MedComm, Volume 6, Issue 5, May 2025.This review probed into the immune factors in the pathogenesis of AA, focusing on the small molecule drugs and biologics for the treatment of AA, and anticipated the research direction in terms of the pathogenesis and targeted therapy of AA. It aims to emphasize the necessity for further exploration of its immunological pathogenesis and therapeutic ...
Tianyou Ma +7 more
wiley +1 more source
Quality of Life in Alopecia Areata: A Sample of Tunisian Patients
Dermatology Research and Practice, 2013 Background. Alopecia areata (AA) has a significant impact on the quality of life and social interaction of those suffering from it. Our aim was to assess the impact of AA on the quality of life. Methods.
Jawaher Masmoudi +7 more
doaj +1 more source
Dermatologic manifestations of hereditary hemochromatosis: A systematic review
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 5, Page 976-986, May 2025.Abstract Hereditary hemochromatosis (HH) is a genetic disorder leading to excessive iron absorption, impacting multiple organs, notably the skin, nails and mucosae. The objective of this study is to elucidate the dermatologic manifestations, associated symptoms, pathophysiology and management recommendations of HH.
Hossein Akbarialiabad +3 more
wiley +1 more source
Bullous hemorrhagic lichen sclerosus of the breast: a report of two cases and review of the literature [PDF]
, 2019 Lichen sclerosus (LS) is a chronic dermatologic condition characterized by atrophic porcelain-appearing plaques that can cause intense discomfort and eventually lead to destruction of local architecture.
Kroger, Kathleen T +3 more
core
Serum Interleukin-4 and Total Immunoglobulin E in Nonatopic Alopecia Areata Patients and HLA-DRB1 Typing [PDF]
, 2010 Background. Interleukin-4 (IL-4), a Th2 cytokine, can stimulate immunoglobulin E (IgE) transcription. No previous studies evaluated the genetic mechanisms in nonatopic AA patients with elevated serum IgE. Objective.
Attia, Enas A. S. +2 more
core +3 more sources
Alopecia Areata and Systemic Lupus Erythematosus: Insights From a Nationwide Case–Control Study
International Journal of Dermatology, EarlyView.
Yonit Wohl +4 more
wiley +1 more source